Clinical Trials Logo

Filter by:
NCT ID: NCT01656863 Not yet recruiting - Attitudes Clinical Trials

Oral Rehydration Therapy in Children With Mild to Moderate Dehydration

Start date: August 2012
Phase: N/A
Study type: Observational

The purpose of this study is to determine parental attitudes towards oral rehydration therapy for children with mild to moderate dehydration.

NCT ID: NCT01656824 Recruiting - Cancer Clinical Trials

Tissue Study of Bv8/PK-2 Inhibition in Human Cancer

Start date: August 2012
Phase: N/A
Study type: Observational

Study hypothesis is that inhibition of Bv8 production in bone marrow cells of a mice wil reduce the rate of growth of a primary human tumor implanted in the mice. we will take mice and transform their bone marrow cells into non-Bv8 producing cells. than we will implant primary human tumor tissue (taken from surgical specimens after informed consent)in those mice and follow-up on the mice.

NCT ID: NCT01656655 Recruiting - Clinical trials for Post Traumatic Stress Disorder

Effect of Post Traumatic Stress Disorder on Parenting

Start date: May 2012
Phase: N/A
Study type: Observational

PTSD affects a wide variety of symptoms, some of which have been shown to disrupt family relationships. This study will examine some of the effects on parenting, from the perspective of the parent with PTSD.

NCT ID: NCT01655914 Completed - Insomnia Clinical Trials

Safety and Pharmacokinetic Study of Sublingual Flumazenil (CRLS035) in Healthy Adults

Start date: July 2010
Phase: Phase 1
Study type: Interventional

This study compare the pharmacokinetic (PK) profile of sublingual CRLS035 (two doses) to I.V flumazenil administration. Selection of study drug dosage: CRLS035 - sublingual Flumazenil will be administrated at a final dosage of 1.1 mg per 100 µl and 2.2 mg (200 µl) in a sublingual spray administration. Currently, Flumazenil is given as an IV drug with a repetitive administration of doses of 0.2 mg up to 3 mg per hour. As the bioavailability of Flumazenil is expected to be lower than the IV administration, 1.1 mg and 2.2 mg will be tested in sublingual delivery. The suggested doses in this study are very safe according to the following data: first, sublingual and buccal administration of Flumazenil have been detailed previously with similar and higher doses with no side effects, secondly, IV dose may reach 3 mg and thirdly, oral administration has been reported as up to 600 mg/dose. The purpose of this study is to determine the single dose PK profile of SL CRLS035. This study is designed to collect short-term safety data and to monitor the PK profile of CRLS035. Primary Objective The primary objective is to determine the single dose safety and PK profile of SL CRLS035 using the marketed IV flumazenil formulation as the comparator. Secondary Objectives The secondary objectives are to (1) characterize the concentration time course of two dose levels of SL CRLS035 to support dose selection for Phase 2 and 3 studies and to evaluate the safety and tolerability of flumazenil formulations; (2)To evaluate the effect of high fat diet and water consumption on the PK profile.

NCT ID: NCT01655537 Completed - Fibromyalgia Clinical Trials

Cognitive Dysfunction in Fibromyalgia Patients

Start date: July 2012
Phase: N/A
Study type: Observational

Fibromyalgia is a common rheumatologic disorder. Many patients complain of cognitive dysfunction as part of their symptoms. The investigators aim to assess this cognitive dysfunction through extensive neuro-cognitive testing.

NCT ID: NCT01655472 Not yet recruiting - Clinical trials for Foetal Differences Between Healthy and Schizophernic Parents

Schizophrenia Imaging

Start date: July 2012
Phase: N/A
Study type: Interventional

Schizophrenia is a common disorder with a lifetime prevalence of about 1%.Genetic studies strongly suggest a genetic component to the inheritance of schizophrenia. Structural neuroimaging studies have provided consistent evidence for brain abnormalities in schizophrenia. The timing of brain abnormalities in schizophrenia has not been determined yet. The investigators hypothesize that brain structural changes can be detected in neonatal life. The investigators hypothesize that offspring of schizophrenic patients will have higher rates of brain structural changes in the neonatal period. The investigators propose to study early development of fetuses in offspring of patients with schizophrenia. The study is a multi-center prospective trial.

NCT ID: NCT01655355 Not yet recruiting - Clinical trials for Revision of the Hip Joint

Revision of the Hip Joint - Prospective Study

Start date: n/a
Phase: N/A
Study type: Observational

Between the years 1999-2011 70 patients went through a revision of the hip joint(revision after not successful Total or Partial Hip Replacement). During the revision the Acetabular implant was found to be stable and it was decided not to replace it. The polyethylene insert was replaced and was fixated using a cement. Our purpose is to evaluate the physical condition of these patients.

NCT ID: NCT01655342 Completed - Clinical trials for Effectiveness of Biodentine® in Pulpotomies Primary Teeth

Assessment of the Effectiveness of Biodentine® in Pulpotomies Primary Teeth

Start date: August 2012
Phase:
Study type: Observational

Clinical and radiographic assessment of Biodentine® as a pulp dressing material for pulpotomy treatment in human primary molars.

NCT ID: NCT01655264 Recruiting - Stroke Clinical Trials

Evaluation of the Gertner Tele-Motion-Rehabilitation System for Stroke Rehabilitation

GertnerTMR
Start date: July 2012
Phase: N/A
Study type: Interventional

The overall goal of the study is to evaluate the clinical effectiveness of a home-based tele-motion-rehabilitation (TMR) program in improving functional status of people who had stroke. We hypothesize that the clinical effectiveness within a mock-up set up in the hospital of the TMR will be greater in comparison to self-training exercise carried out at home in improving outcomes of Range of Motion and functional performance of the weak upper extremity. Twenty-four subjects who had a stroke, aged between 18 and 80 years, and living at home will participate. Subjects will be 2-72 months post stroke, and no longer receiving rehabilitation as in or out patient. They will have moderate impairment of the affected upper extremity determined by range of motion (ROM). Subjects will be evaluated for motor and cognitive abilities for a total of 5-6 hours by a skilled therapist who will be blind to group's assignment of the subjects. The evaluations will be repeated 3 times, once before the intervention commences, once immediately following the intervention and once four weeks after the intervention. Subjects will be randomized into the two groups (TMR versus self-training treatment) with matching for level of impairment of the upper extremity by a person who is not part of the study. Each subject will receive twelve 45-60 min sessions over 4 weeks while seated. The control group will receive self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. The experimental group will receive TMR treatment of comparable duration and intensity to those in the conventional treatment group with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. The Gertner TMR system is implemented via Microsoft's Kinect three-dimensional) camera-based gesture recognition technology. Using the patient's natural hand and body movements control all activity within customized computer games. The system runs off a standard desktop computer and is displayed on a large television screen.

NCT ID: NCT01654926 Completed - Heart Failure Clinical Trials

Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers

Start date: December 2012
Phase: N/A
Study type: Observational

Ultrafiltration (UF) technology is unique for its ability to extract fluid as an isotonic solution, therefore not causing substantial changes in NaCl concentrations, and the use of peripheral veins makes it feasible to use in out of hospital medical centers, for non compensated Heart Failure (HF) with a low response to diuretics. The use of UF in the United States and Europe in out of hospital HF centers is accepted as daily practice. Therefore the hypothesis of this study is that it is feasible for a professional team to effectively use the UF for short courses on non compensated HF patients with low or no response to Diuretics, in a dedicated out of hospital HF center.